The University of Chicago Header Logo

Ezra Cohen

Concepts (683)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Head and Neck Neoplasms
131
2026
1091
18.540
Why?
Carcinoma, Squamous Cell
90
2024
1107
12.230
Why?
Neoplasm Recurrence, Local
50
2026
1538
5.410
Why?
Antineoplastic Combined Chemotherapy Protocols
62
2026
2666
5.220
Why?
Antineoplastic Agents
50
2024
2386
5.070
Why?
Quinazolines
29
2023
222
4.530
Why?
Thyroid Neoplasms
19
2024
470
3.930
Why?
ErbB Receptors
29
2021
517
3.790
Why?
Protein Kinase Inhibitors
27
2024
642
3.320
Why?
Mouth Neoplasms
18
2026
223
3.090
Why?
Antibodies, Monoclonal, Humanized
30
2026
1105
2.800
Why?
Chemoradiotherapy
24
2026
337
2.690
Why?
Cetuximab
16
2022
119
2.340
Why?
Neoplasms
30
2026
3382
2.090
Why?
Biomarkers, Tumor
19
2025
1786
2.000
Why?
Papillomavirus Infections
12
2023
311
1.790
Why?
Humans
238
2026
98799
1.770
Why?
Disease-Free Survival
36
2021
1196
1.600
Why?
Oropharyngeal Neoplasms
7
2023
152
1.600
Why?
B7-H1 Antigen
12
2026
333
1.550
Why?
Immunotherapy
14
2024
831
1.500
Why?
Indazoles
8
2015
65
1.480
Why?
Imidazoles
8
2015
142
1.440
Why?
Aged
101
2026
21986
1.430
Why?
Methotrexate
10
2019
229
1.420
Why?
TOR Serine-Threonine Kinases
11
2021
224
1.370
Why?
Middle Aged
102
2026
29642
1.270
Why?
Sirolimus
8
2018
181
1.270
Why?
Carcinoma, Non-Small-Cell Lung
10
2024
1177
1.230
Why?
Programmed Cell Death 1 Receptor
10
2024
201
1.220
Why?
Female
126
2026
51997
1.220
Why?
Indoles
11
2023
340
1.190
Why?
Treatment Outcome
58
2026
9806
1.180
Why?
Lung Neoplasms
12
2024
2474
1.170
Why?
Male
117
2026
47475
1.140
Why?
Anilides
6
2016
50
1.120
Why?
Drug Resistance, Neoplasm
9
2026
671
1.110
Why?
Neoplasm Metastasis
23
2025
1102
1.100
Why?
Pyridines
9
2022
317
1.100
Why?
Antineoplastic Agents, Immunological
7
2020
238
1.090
Why?
Adult
86
2026
29698
1.040
Why?
Lymphocytes, Tumor-Infiltrating
2
2025
168
0.980
Why?
Aged, 80 and over
45
2026
7461
0.980
Why?
Molecular Targeted Therapy
12
2024
331
0.970
Why?
Protein-Tyrosine Kinases
6
2012
305
0.920
Why?
Cisplatin
10
2025
578
0.910
Why?
Neoplasm Staging
26
2019
2087
0.890
Why?
Quality of Life
13
2021
1904
0.850
Why?
Papillomaviridae
8
2024
184
0.790
Why?
Combined Modality Therapy
25
2020
1754
0.790
Why?
Induction Chemotherapy
11
2021
152
0.780
Why?
Everolimus
4
2022
35
0.770
Why?
Precancerous Conditions
6
2024
221
0.760
Why?
Fluorocarbons
1
2023
64
0.750
Why?
Mutation
20
2024
4443
0.730
Why?
Salivary Gland Neoplasms
4
2020
88
0.720
Why?
Iodine Radioisotopes
6
2023
145
0.690
Why?
Proto-Oncogene Proteins c-akt
7
2016
369
0.690
Why?
Survival Analysis
20
2020
1530
0.690
Why?
Cell Line, Tumor
19
2026
2913
0.690
Why?
Carcinoma, Papillary
5
2016
166
0.670
Why?
Phenylurea Compounds
6
2015
112
0.670
Why?
Skin Neoplasms
3
2022
638
0.670
Why?
Prognosis
24
2026
4139
0.660
Why?
Tumor Microenvironment
9
2026
621
0.640
Why?
Antibodies, Monoclonal
10
2021
1422
0.640
Why?
Disease Management
4
2021
378
0.630
Why?
Signal Transduction
19
2026
3642
0.600
Why?
Laryngeal Neoplasms
4
2013
89
0.600
Why?
Nasopharyngeal Neoplasms
3
2015
48
0.600
Why?
Human papillomavirus 16
5
2023
46
0.590
Why?
Vascular Endothelial Growth Factor A
6
2023
402
0.580
Why?
Cancer Vaccines
1
2020
168
0.580
Why?
Angiogenesis Inhibitors
8
2023
281
0.570
Why?
Clinical Trials as Topic
11
2016
1128
0.550
Why?
Antigens, Neoplasm
1
2020
366
0.550
Why?
Kaplan-Meier Estimate
9
2018
909
0.550
Why?
Benzazepines
1
2018
64
0.550
Why?
Proto-Oncogene Proteins c-kit
2
2015
80
0.540
Why?
Survivors
2
2016
211
0.530
Why?
Algorithms
3
2025
2005
0.510
Why?
Quinolines
2
2015
97
0.510
Why?
Fluorouracil
15
2014
543
0.510
Why?
Patient Selection
8
2021
725
0.490
Why?
Killer Cells, Natural
2
2017
298
0.490
Why?
Metformin
3
2026
134
0.490
Why?
Research Design
5
2014
652
0.480
Why?
Survival Rate
12
2016
2057
0.480
Why?
Radiation-Sensitizing Agents
3
2020
99
0.480
Why?
Mice, Nude
9
2019
829
0.480
Why?
Hypopharyngeal Neoplasms
2
2013
15
0.470
Why?
Precision Medicine
4
2021
512
0.460
Why?
Carcinoma, Adenoid Cystic
2
2015
46
0.460
Why?
Dasatinib
1
2015
38
0.460
Why?
Drug Administration Schedule
8
2018
837
0.450
Why?
Erlotinib Hydrochloride
6
2016
88
0.450
Why?
Aftercare
1
2016
93
0.440
Why?
Glutamates
2
2012
85
0.430
Why?
Anticarcinogenic Agents
2
2016
71
0.430
Why?
Antibiotics, Antineoplastic
2
2012
111
0.430
Why?
Administration, Oral
10
2021
677
0.430
Why?
Antibody-Dependent Cell Cytotoxicity
1
2015
42
0.430
Why?
Double-Blind Method
9
2026
1793
0.430
Why?
Adaptor Proteins, Signal Transducing
4
2016
316
0.420
Why?
Maximum Tolerated Dose
10
2017
265
0.420
Why?
Receptors, Vascular Endothelial Growth Factor
6
2023
58
0.420
Why?
Guanine
2
2012
194
0.410
Why?
Benzimidazoles
2
2012
120
0.410
Why?
Neovascularization, Pathologic
3
2015
356
0.400
Why?
Pyrroles
4
2015
166
0.400
Why?
Radiodermatitis
1
2013
10
0.400
Why?
Mucositis
1
2013
18
0.390
Why?
Neoplasm Invasiveness
4
2012
583
0.390
Why?
Palliative Care
2
2015
291
0.390
Why?
Radiopharmaceuticals
2
2015
214
0.380
Why?
Food-Drug Interactions
1
2013
19
0.380
Why?
Adenocarcinoma
4
2023
1215
0.380
Why?
Antimetabolites, Antineoplastic
4
2017
246
0.370
Why?
Consensus
1
2014
308
0.370
Why?
Class I Phosphatidylinositol 3-Kinases
5
2021
84
0.370
Why?
Hot Temperature
1
2013
232
0.360
Why?
Publishing
1
2013
97
0.360
Why?
Information Dissemination
1
2013
135
0.360
Why?
Medical Oncology
4
2019
426
0.360
Why?
Hydroxyurea
12
2014
233
0.360
Why?
Health Status
1
2014
388
0.360
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2011
18
0.350
Why?
Practice Guidelines as Topic
3
2013
1116
0.350
Why?
Clinical Trials, Phase III as Topic
6
2022
172
0.350
Why?
Carcinoma, Large Cell
1
2011
38
0.340
Why?
Mice
16
2026
12762
0.340
Why?
Surveys and Questionnaires
6
2018
3058
0.340
Why?
Periodicals as Topic
1
2013
175
0.340
Why?
Dose-Response Relationship, Drug
11
2021
1949
0.330
Why?
Adenocarcinoma, Follicular
1
2012
60
0.330
Why?
Mitogen-Activated Protein Kinases
3
2008
218
0.330
Why?
Animals
23
2026
29045
0.330
Why?
Sulfonamides
5
2016
352
0.330
Why?
Bevacizumab
6
2011
255
0.330
Why?
Leukoplakia, Oral
3
2024
16
0.320
Why?
Radiotherapy Dosage
10
2016
478
0.310
Why?
Thyroid Gland
1
2012
297
0.310
Why?
Receptor Protein-Tyrosine Kinases
2
2011
160
0.310
Why?
Disease Progression
10
2020
1621
0.300
Why?
Patient Care Team
1
2013
318
0.300
Why?
Cohort Studies
8
2025
3242
0.300
Why?
Cyclin-Dependent Kinase Inhibitor p16
2
2022
110
0.300
Why?
Clinical Trials, Phase II as Topic
4
2022
168
0.300
Why?
Mouth Mucosa
3
2021
72
0.300
Why?
Fluorodeoxyglucose F18
1
2010
146
0.300
Why?
Proto-Oncogene Proteins c-ret
3
2016
24
0.300
Why?
Immunohistochemistry
7
2020
1818
0.290
Why?
Diarrhea
4
2014
180
0.290
Why?
Randomized Controlled Trials as Topic
6
2022
995
0.290
Why?
Protein Kinase C-alpha
1
2009
29
0.280
Why?
Skin
1
2012
592
0.280
Why?
Biopsy
4
2021
1226
0.280
Why?
Thalidomide
3
2015
57
0.270
Why?
Positron-Emission Tomography
1
2010
354
0.270
Why?
Radiation Tolerance
4
2016
179
0.270
Why?
Proto-Oncogene Proteins B-raf
3
2016
170
0.270
Why?
ras Proteins
3
2016
137
0.270
Why?
Xenograft Model Antitumor Assays
7
2021
559
0.270
Why?
Pharmacogenetics
1
2012
474
0.260
Why?
Lymphocyte Activation
3
2020
825
0.260
Why?
Esophageal Neoplasms
3
2017
355
0.260
Why?
Radiotherapy
6
2020
325
0.260
Why?
DNA-Binding Proteins
4
2016
1275
0.260
Why?
United States
15
2020
8387
0.250
Why?
Chemotherapy, Adjuvant
7
2021
527
0.250
Why?
Protein Kinases
1
2008
211
0.240
Why?
Retreatment
5
2015
106
0.240
Why?
Niacinamide
5
2014
105
0.240
Why?
Neoadjuvant Therapy
4
2024
477
0.240
Why?
Triazines
1
2007
55
0.240
Why?
T-Lymphocytes
4
2026
1335
0.240
Why?
B-Lymphocyte Subsets
1
2026
38
0.240
Why?
DNA, Neoplasm
3
2017
267
0.240
Why?
Eating
1
2007
164
0.240
Why?
Piperazines
4
2022
308
0.240
Why?
Retrospective Studies
17
2023
11104
0.240
Why?
Time Factors
9
2020
5586
0.230
Why?
Apoptosis
5
2023
1754
0.230
Why?
Epidermal Growth Factor
1
2006
116
0.230
Why?
Cell Proliferation
6
2026
1801
0.230
Why?
Young Adult
11
2019
7598
0.230
Why?
B-Lymphocytes
2
2021
737
0.230
Why?
Deoxycytidine
2
2011
218
0.230
Why?
Immunotoxins
1
2005
16
0.230
Why?
Vascular Endothelial Growth Factor Receptor-2
4
2015
82
0.230
Why?
Ribosomal Protein S6 Kinases, 70-kDa
3
2018
46
0.230
Why?
Oligonucleotides, Antisense
1
2005
70
0.220
Why?
Tongue Neoplasms
3
2017
51
0.220
Why?
Cyclic AMP-Dependent Protein Kinases
1
2026
119
0.220
Why?
Genomics
4
2015
914
0.220
Why?
Tumor Escape
3
2020
56
0.220
Why?
Immunologic Factors
3
2021
180
0.220
Why?
Drug Approval
2
2019
68
0.220
Why?
Viral Vaccines
2
2003
38
0.220
Why?
Protein Kinase C
1
2006
267
0.220
Why?
United States Food and Drug Administration
2
2019
165
0.210
Why?
Fatigue
3
2016
187
0.210
Why?
Vinblastine
2
2002
84
0.210
Why?
Proto-Oncogene Proteins p21(ras)
2
2020
186
0.210
Why?
Genes, p53
2
2015
108
0.210
Why?
Veterans
2
2023
120
0.210
Why?
Risk Factors
11
2019
6295
0.210
Why?
Phosphatidylinositol 3-Kinases
3
2015
286
0.210
Why?
Evidence-Based Dentistry
3
2017
16
0.200
Why?
Clinical Protocols
2
2014
156
0.200
Why?
Chromosome Deletion
2
2015
219
0.200
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2026
255
0.200
Why?
MicroRNAs
1
2009
609
0.200
Why?
Receptor, ErbB-3
2
2021
19
0.200
Why?
Aminobenzoates
2
2022
7
0.200
Why?
Gene Expression Regulation, Neoplastic
4
2024
1400
0.200
Why?
Fluorine
1
2023
11
0.200
Why?
Drug Synergism
4
2026
317
0.200
Why?
Mitochondria
1
2007
653
0.190
Why?
Deglutition
3
2013
87
0.190
Why?
Smoking
5
2014
676
0.190
Why?
Platinum
5
2016
68
0.190
Why?
MAP Kinase Signaling System
2
2016
212
0.180
Why?
Immunomodulation
2
2021
65
0.180
Why?
Pilot Projects
2
2023
978
0.180
Why?
Biomarkers
6
2021
2026
0.180
Why?
Neoplasms, Second Primary
3
2011
244
0.180
Why?
Alcohol Drinking
4
2013
302
0.180
Why?
Magnetic Resonance Spectroscopy
1
2023
271
0.180
Why?
Cell Cycle
3
2010
519
0.180
Why?
Carboplatin
6
2019
331
0.180
Why?
Follow-Up Studies
10
2018
4049
0.180
Why?
Oligopeptides
2
2022
205
0.180
Why?
Adenoviridae
2
2003
341
0.170
Why?
Pain Management
2
2015
198
0.170
Why?
Pemetrexed
2
2012
76
0.170
Why?
Benzenesulfonates
3
2011
49
0.170
Why?
Deglutition Disorders
2
2016
126
0.170
Why?
Gene Deletion
2
2014
355
0.170
Why?
Muscle Neoplasms
1
2001
16
0.170
Why?
Immunoconjugates
1
2022
140
0.170
Why?
Mechanistic Target of Rapamycin Complex 1
1
2021
51
0.170
Why?
Drug Monitoring
2
2019
167
0.160
Why?
Carcinoma
3
2015
442
0.160
Why?
Genetic Therapy
2
2012
374
0.160
Why?
Clinical Competence
2
2018
873
0.160
Why?
Taxoids
2
2014
127
0.160
Why?
Immunogenicity, Vaccine
1
2020
22
0.160
Why?
Salvage Therapy
2
2016
241
0.160
Why?
Vaccines, Subunit
1
2020
54
0.160
Why?
Immune System
1
2021
106
0.160
Why?
Germ-Line Mutation
2
2022
404
0.160
Why?
Oncolytic Virotherapy
1
2020
36
0.160
Why?
Cell-Penetrating Peptides
1
2020
6
0.160
Why?
Blood Pressure
3
2014
923
0.160
Why?
Paclitaxel
6
2012
484
0.150
Why?
Rimantadine
1
2019
8
0.150
Why?
Radiotherapy, Intensity-Modulated
3
2019
200
0.150
Why?
Heterografts
2
2017
121
0.150
Why?
Doxorubicin
1
2001
285
0.150
Why?
Prospective Studies
6
2022
4837
0.150
Why?
Quinolones
1
2020
59
0.150
Why?
Oncogene Proteins, Viral
1
2019
34
0.150
Why?
Clinical Trials, Phase I as Topic
3
2014
154
0.150
Why?
Microbiota
1
2026
473
0.150
Why?
Nomograms
1
2019
34
0.150
Why?
Age Factors
3
2019
1976
0.150
Why?
Melanoma
1
2024
523
0.150
Why?
Decision Support Techniques
1
2020
193
0.140
Why?
Genotype
2
2015
1895
0.140
Why?
Models, Immunological
1
2019
86
0.140
Why?
CTLA-4 Antigen
1
2019
147
0.140
Why?
Palliative Medicine
1
2018
11
0.140
Why?
Brain Neoplasms
1
2024
845
0.140
Why?
Chromosomes, Human, Pair 3
2
2015
55
0.140
Why?
Carcinoma, Neuroendocrine
3
2013
48
0.130
Why?
Toll-Like Receptor 9
1
2017
25
0.130
Why?
Toll-Like Receptor 7
1
2017
16
0.130
Why?
Biological Products
1
2020
191
0.130
Why?
Cell Growth Processes
2
2009
83
0.130
Why?
Cost-Benefit Analysis
3
2020
521
0.130
Why?
Immunoglobulin G
1
2019
481
0.130
Why?
Risk Assessment
6
2016
2604
0.130
Why?
Neoplasm Grading
2
2018
425
0.130
Why?
Administration, Intravenous
1
2017
64
0.130
Why?
Transforming Growth Factor alpha
2
2009
49
0.130
Why?
Gene Expression
2
2014
1322
0.130
Why?
Confidence Intervals
4
2019
221
0.130
Why?
Evidence-Based Medicine
2
2015
483
0.130
Why?
Immune Tolerance
2
2019
388
0.130
Why?
Base Sequence
3
2014
2224
0.130
Why?
Population Surveillance
2
2018
218
0.130
Why?
Models, Biological
3
2014
1806
0.130
Why?
Mice, Inbred C3H
1
2017
370
0.120
Why?
SOX9 Transcription Factor
1
2016
31
0.120
Why?
Class Ib Phosphatidylinositol 3-Kinase
1
2016
4
0.120
Why?
Proto-Oncogenes
1
2016
60
0.120
Why?
Urinary Bladder Neoplasms
1
2001
403
0.120
Why?
Peptides
2
2022
671
0.120
Why?
Pyrazines
2
2022
98
0.120
Why?
Macrophages
2
2017
641
0.120
Why?
Predictive Value of Tests
2
2020
1792
0.120
Why?
Tomography, X-Ray Computed
3
2019
2680
0.120
Why?
Accessory Nerve Diseases
1
2016
1
0.120
Why?
Dental Caries
1
2016
4
0.120
Why?
Trismus
1
2016
6
0.120
Why?
Xerostomia
1
2016
11
0.120
Why?
Voice Disorders
1
2016
7
0.120
Why?
Respiratory Aspiration
1
2016
6
0.120
Why?
Robotic Surgical Procedures
1
2023
425
0.120
Why?
Periodontitis
1
2016
8
0.120
Why?
Taste Disorders
1
2016
11
0.120
Why?
American Cancer Society
1
2016
15
0.120
Why?
Stomatitis
1
2016
30
0.120
Why?
Vestibular Neuronitis
1
2016
5
0.120
Why?
Benzamides
2
2022
260
0.120
Why?
Osteonecrosis
1
2016
21
0.120
Why?
In Situ Hybridization, Fluorescence
3
2012
369
0.120
Why?
Dental Care
1
2016
15
0.120
Why?
Dystonia
1
2016
32
0.120
Why?
Bursitis
1
2016
15
0.120
Why?
Peptide Hormones
1
2016
30
0.120
Why?
Neck Muscles
1
2016
22
0.120
Why?
Pyrimidines
3
2017
416
0.120
Why?
Pyrimidinones
1
2016
51
0.110
Why?
Circulating Tumor DNA
1
2017
82
0.110
Why?
Proto-Oncogene Proteins
2
2010
687
0.110
Why?
Mass Screening
2
2012
753
0.110
Why?
Drug Evaluation, Preclinical
1
2015
111
0.110
Why?
Pyridones
1
2016
74
0.110
Why?
Societies, Medical
1
2019
687
0.110
Why?
Collagen Type I
1
2015
75
0.110
Why?
Matrix Metalloproteinases
1
2015
30
0.110
Why?
Peripheral Nervous System Diseases
1
2016
94
0.110
Why?
Multivariate Analysis
3
2019
1007
0.110
Why?
Drug Screening Assays, Antitumor
2
2015
87
0.110
Why?
Sleep Apnea Syndromes
1
2016
109
0.110
Why?
Pneumonia, Aspiration
1
2014
20
0.110
Why?
Receptors, IgG
1
2015
70
0.110
Why?
Phosphorylation
2
2018
1148
0.110
Why?
Lymphedema
1
2016
92
0.100
Why?
Health Promotion
1
2016
175
0.100
Why?
Sleep Wake Disorders
1
2016
139
0.100
Why?
Ubiquitin-Activating Enzymes
1
2014
7
0.100
Why?
Autophagy-Related Protein 7
1
2014
12
0.100
Why?
Drug Interactions
3
2011
240
0.100
Why?
Proteomics
2
2022
282
0.100
Why?
Stomach Neoplasms
1
2017
321
0.100
Why?
Sequestosome-1 Protein
1
2014
23
0.100
Why?
Tumor Virus Infections
1
2014
83
0.100
Why?
Gastroesophageal Reflux
1
2016
131
0.100
Why?
Peptide Fragments
1
2016
480
0.100
Why?
Quinoxalines
1
2014
51
0.100
Why?
DNA Primers
2
2014
530
0.100
Why?
Transcription Factors
2
2016
1724
0.100
Why?
Licensure
1
2013
6
0.100
Why?
Tissue Array Analysis
1
2014
135
0.100
Why?
Education, Medical, Graduate
1
2018
455
0.100
Why?
Regression Analysis
2
2019
578
0.100
Why?
Population Groups
1
2013
44
0.100
Why?
Peer Review
1
2013
20
0.100
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
2
2013
83
0.100
Why?
Aminolevulinic Acid
1
2013
22
0.100
Why?
Heterocyclic Compounds, 3-Ring
1
2014
56
0.100
Why?
Erythropoiesis
1
2013
53
0.100
Why?
Statistics, Nonparametric
3
2009
304
0.100
Why?
Economics, Pharmaceutical
1
2013
8
0.100
Why?
Focus Groups
1
2014
215
0.100
Why?
Photosensitizing Agents
1
2013
53
0.100
Why?
Area Under Curve
5
2014
341
0.100
Why?
Pediatrics
1
2018
422
0.100
Why?
Antineoplastic Agents, Phytogenic
2
2012
272
0.100
Why?
Italy
1
2013
113
0.100
Why?
Magnetics
1
2013
39
0.090
Why?
Anxiety
1
2016
376
0.090
Why?
CD8-Positive T-Lymphocytes
1
2017
701
0.090
Why?
Micelles
1
2013
57
0.090
Why?
Gastrostomy
1
2013
68
0.090
Why?
Interviews as Topic
1
2014
390
0.090
Why?
Magnetic Resonance Imaging
2
2023
3622
0.090
Why?
Citrus paradisi
1
2012
5
0.090
Why?
Hypothyroidism
1
2016
299
0.090
Why?
Breast Neoplasms
2
2017
3303
0.090
Why?
United Kingdom
1
2013
217
0.090
Why?
Photochemotherapy
1
2013
101
0.090
Why?
Ketoconazole
1
2012
23
0.090
Why?
Lymphopenia
1
2012
31
0.090
Why?
Gene Expression Profiling
3
2014
1572
0.090
Why?
Stress, Psychological
1
2016
384
0.090
Why?
DNA Repair
1
2014
363
0.090
Why?
Dose-Response Relationship, Radiation
2
2009
193
0.090
Why?
Sexual Partners
1
2013
107
0.090
Why?
Platinum Compounds
1
2012
29
0.090
Why?
Intracellular Signaling Peptides and Proteins
1
2014
405
0.090
Why?
Biopsy, Needle
1
2012
225
0.090
Why?
Autophagy
1
2014
176
0.090
Why?
Qualitative Research
1
2014
424
0.090
Why?
Hyperlipidemias
1
2012
93
0.090
Why?
RNA, Viral
1
2013
289
0.090
Why?
Radiography
2
2014
763
0.090
Why?
Colorectal Neoplasms
2
2011
1120
0.090
Why?
RNA, Small Interfering
2
2010
573
0.090
Why?
Bibenzyls
1
2011
2
0.090
Why?
Lactams, Macrocyclic
1
2011
15
0.080
Why?
Exanthema
1
2012
43
0.080
Why?
Benzoquinones
1
2011
27
0.080
Why?
Valproic Acid
1
2011
26
0.080
Why?
Radiotherapy, Adjuvant
3
2008
325
0.080
Why?
Feasibility Studies
2
2019
818
0.080
Why?
Tumor Suppressor Protein p53
1
2014
470
0.080
Why?
Depsipeptides
1
2011
30
0.080
Why?
Hyperglycemia
1
2012
187
0.080
Why?
Tracheotomy
1
2011
18
0.080
Why?
Hydroxamic Acids
1
2011
53
0.080
Why?
Carbazoles
1
2011
31
0.080
Why?
Bortezomib
1
2011
83
0.080
Why?
Boronic Acids
1
2011
56
0.080
Why?
Psoriasis
1
2014
262
0.080
Why?
HSP90 Heat-Shock Proteins
1
2011
45
0.080
Why?
Depression
1
2016
625
0.080
Why?
In Situ Nick-End Labeling
1
2011
122
0.080
Why?
Imatinib Mesylate
1
2011
129
0.080
Why?
Drug Eruptions
1
2011
35
0.080
Why?
Chemoprevention
1
2011
93
0.080
Why?
Oligonucleotides
1
2011
93
0.080
Why?
Camptothecin
1
2011
198
0.080
Why?
Cyclin D1
1
2010
86
0.080
Why?
Nanoparticles
1
2013
219
0.080
Why?
Neoplasm Transplantation
1
2011
400
0.080
Why?
Probability
5
2009
356
0.080
Why?
Histone Deacetylase Inhibitors
1
2011
109
0.080
Why?
Speech
1
2010
91
0.080
Why?
Sexual Behavior
1
2013
343
0.080
Why?
Airway Obstruction
1
2011
112
0.080
Why?
Piperidines
1
2011
177
0.080
Why?
DNA Mutational Analysis
2
2015
554
0.070
Why?
Cell Cycle Proteins
2
2010
420
0.070
Why?
Antigen-Presenting Cells
2
2021
147
0.070
Why?
Cell Line
2
2011
2484
0.070
Why?
Tumor Cells, Cultured
1
2011
1029
0.070
Why?
Thermography
1
2009
13
0.070
Why?
Transplantation, Heterologous
1
2010
375
0.070
Why?
Mass Spectrometry
1
2010
189
0.070
Why?
Receptors, Growth Factor
1
2009
52
0.070
Why?
Cyclin E
1
2009
28
0.070
Why?
Endpoint Determination
1
2009
65
0.070
Why?
Demography
1
2009
193
0.070
Why?
Radiotherapy, High-Energy
1
2008
43
0.070
Why?
Cell Survival
1
2011
1018
0.070
Why?
Internship and Residency
1
2018
1132
0.070
Why?
Amino Acid Sequence
2
2016
2011
0.070
Why?
Referral and Consultation
1
2012
419
0.070
Why?
Oligonucleotide Array Sequence Analysis
1
2010
700
0.070
Why?
Biomedical Research
1
2013
477
0.070
Why?
Analysis of Variance
2
2008
890
0.070
Why?
Molecular Sequence Data
2
2016
2897
0.070
Why?
Adolescent
6
2019
10168
0.070
Why?
Research
1
2009
258
0.070
Why?
Economics, Medical
1
2007
6
0.070
Why?
Radiosurgery
1
2011
352
0.070
Why?
Drug Packaging
1
2007
7
0.070
Why?
Polymorphism, Genetic
1
2011
832
0.060
Why?
Drug Labeling
1
2007
44
0.060
Why?
DNA
1
2012
1274
0.060
Why?
DNA, Mitochondrial
1
2007
211
0.060
Why?
Benzophenanthridines
1
2006
23
0.060
Why?
Carcinoma, Renal Cell
1
2011
384
0.060
Why?
Butadienes
1
2006
33
0.060
Why?
Phenanthridines
1
2006
25
0.060
Why?
Phosphorylcholine
1
2006
22
0.060
Why?
Cell Dedifferentiation
1
2006
10
0.060
Why?
Alkaloids
1
2006
48
0.060
Why?
Remission Induction
3
2016
764
0.060
Why?
Surgical Flaps
1
2008
252
0.060
Why?
Rituximab
1
2026
138
0.060
Why?
Cyclooxygenase 2 Inhibitors
1
2026
36
0.060
Why?
Phenotype
1
2012
2673
0.060
Why?
Nitriles
1
2006
172
0.060
Why?
Kidney Neoplasms
1
2011
556
0.060
Why?
American Dental Association
2
2017
9
0.060
Why?
Keratinocytes
1
2006
156
0.060
Why?
CRISPR-Cas Systems
1
2026
115
0.050
Why?
Enzyme Activation
1
2006
679
0.050
Why?
Cyclooxygenase Inhibitors
1
2004
38
0.050
Why?
Preoperative Care
2
2006
420
0.050
Why?
Proteasome Inhibitors
1
2004
52
0.050
Why?
Hypoxia-Inducible Factor 1
1
2004
44
0.050
Why?
SEER Program
2
2016
252
0.050
Why?
Early Detection of Cancer
3
2017
563
0.050
Why?
Neutrophils
1
2026
346
0.050
Why?
Incidence
3
2017
1798
0.050
Why?
Mouthwashes
1
2003
6
0.050
Why?
Cell Transformation, Neoplastic
1
2006
466
0.050
Why?
Colonic Neoplasms
1
2008
592
0.050
Why?
DNA Copy Number Variations
2
2015
207
0.050
Why?
Forecasting
2
2019
298
0.050
Why?
Hypoxia-Inducible Factor 1, alpha Subunit
1
2004
177
0.050
Why?
Vascular Endothelial Growth Factor Receptor-3
2
2015
26
0.050
Why?
Mitogen-Activated Protein Kinase 3
1
2003
68
0.050
Why?
Intubation, Gastrointestinal
1
2003
30
0.050
Why?
CCAAT-Enhancer-Binding Protein-beta
2
2016
15
0.050
Why?
Interferons
1
2023
114
0.050
Why?
Odds Ratio
2
2018
728
0.050
Why?
Disease Models, Animal
2
2020
2581
0.050
Why?
Infusions, Intravenous
3
2009
403
0.050
Why?
Infant
2
2023
3368
0.050
Why?
Antibodies, Neoplasm
1
2022
87
0.040
Why?
Gene Amplification
2
2015
142
0.040
Why?
Isotretinoin
1
2002
22
0.040
Why?
Vascular Endothelial Growth Factor Receptor-1
2
2015
111
0.040
Why?
RNA, Neoplasm
1
2021
87
0.040
Why?
Illinois
1
2003
531
0.040
Why?
Interferon-alpha
1
2002
191
0.040
Why?
Single-Blind Method
1
2021
160
0.040
Why?
Sex Factors
2
2014
1144
0.040
Why?
Medicare
2
2016
528
0.040
Why?
Inflammation
2
2019
1134
0.040
Why?
Cytodiagnosis
2
2012
48
0.040
Why?
Germany
1
2021
84
0.040
Why?
Lymphopoiesis
1
2021
48
0.040
Why?
Structure-Activity Relationship
1
2001
429
0.040
Why?
Placebos
1
2021
210
0.040
Why?
Antibody Formation
1
2021
173
0.040
Why?
Urothelium
1
2001
67
0.040
Why?
Standard of Care
1
2021
71
0.040
Why?
Nuclear Proteins
1
2004
757
0.040
Why?
RAW 264.7 Cells
1
2019
21
0.040
Why?
Peptide Hydrolases
1
2020
99
0.040
Why?
Treatment Adherence and Compliance
1
2019
5
0.040
Why?
Models, Economic
1
2020
72
0.040
Why?
Permeability
1
2019
145
0.040
Why?
Thinness
1
2019
49
0.040
Why?
Child
3
2018
7771
0.040
Why?
Receptors, Cytokine
1
2019
31
0.040
Why?
Healthy Volunteers
1
2019
154
0.040
Why?
Histocompatibility Antigens Class II
1
2019
174
0.040
Why?
Smokers
1
2019
64
0.040
Why?
Employment
1
2019
67
0.040
Why?
Quality-Adjusted Life Years
1
2020
170
0.040
Why?
Hospitals, Veterans
1
2018
24
0.040
Why?
Epithelial Cells
1
2022
710
0.030
Why?
Diffusion of Innovation
1
2019
81
0.030
Why?
Equivalence Trials as Topic
1
2018
7
0.030
Why?
Drug Delivery Systems
1
2020
202
0.030
Why?
Training Support
1
2018
23
0.030
Why?
Interdisciplinary Studies
1
2018
19
0.030
Why?
Insulin-Like Growth Factor II
1
2018
32
0.030
Why?
Antigen Presentation
1
2019
234
0.030
Why?
Herpesvirus 1, Human
1
2020
210
0.030
Why?
Laryngectomy
1
2018
26
0.030
Why?
Hypoglycemic Agents
1
2021
416
0.030
Why?
Organ Specificity
1
2019
287
0.030
Why?
Clinical Decision-Making
1
2020
306
0.030
Why?
Down-Regulation
1
2019
529
0.030
Why?
Margins of Excision
1
2018
50
0.030
Why?
Dendritic Cells
1
2022
547
0.030
Why?
Patient Reported Outcome Measures
1
2021
337
0.030
Why?
Drug-Related Side Effects and Adverse Reactions
1
2020
220
0.030
Why?
Insulin-Like Growth Factor I
1
2018
118
0.030
Why?
Reference Values
2
2009
608
0.030
Why?
Enteral Nutrition
1
2018
103
0.030
Why?
Mouth
1
2017
53
0.030
Why?
Autoimmunity
1
2019
195
0.030
Why?
HEK293 Cells
1
2019
724
0.030
Why?
Leukocytes, Mononuclear
1
2018
213
0.030
Why?
Diagnostic Tests, Routine
1
2017
63
0.030
Why?
Neck Dissection
2
2008
67
0.030
Why?
Acrylamides
1
2017
37
0.030
Why?
MDS1 and EVI1 Complex Locus Protein
1
2016
7
0.030
Why?
Regulatory-Associated Protein of mTOR
1
2016
12
0.030
Why?
Proportional Hazards Models
1
2019
925
0.030
Why?
Osteonectin
1
2016
22
0.030
Why?
Aniline Compounds
1
2017
64
0.030
Why?
National Cancer Institute (U.S.)
1
2016
77
0.030
Why?
Program Evaluation
1
2018
349
0.030
Why?
MCF-7 Cells
1
2016
123
0.030
Why?
Decision Making
1
2002
691
0.030
Why?
Immunoenzyme Techniques
1
2016
291
0.030
Why?
Financing, Government
1
2016
26
0.030
Why?
Loss of Heterozygosity
1
2016
85
0.030
Why?
Comorbidity
1
2019
1037
0.030
Why?
Snake Venoms
1
2015
10
0.030
Why?
Bayes Theorem
1
2017
423
0.030
Why?
Microfilament Proteins
1
2016
211
0.030
Why?
Exons
1
2017
458
0.030
Why?
Acid Anhydride Hydrolases
1
2015
13
0.030
Why?
RNA Interference
1
2016
388
0.030
Why?
Cause of Death
1
2016
279
0.030
Why?
Cell Division
1
2016
690
0.030
Why?
Lymphatic Metastasis
1
2016
519
0.030
Why?
Biological Availability
1
2014
86
0.030
Why?
Human papillomavirus 18
1
2014
22
0.030
Why?
Nonlinear Dynamics
1
2014
66
0.030
Why?
Tissue Distribution
1
2014
290
0.030
Why?
Gene Knockout Techniques
1
2014
85
0.030
Why?
Transcription, Genetic
1
2019
1136
0.030
Why?
Protein Interaction Maps
1
2014
54
0.030
Why?
Anorexia
1
2014
26
0.030
Why?
Metabolic Clearance Rate
1
2014
118
0.030
Why?
Immunoblotting
1
2014
273
0.030
Why?
Prevalence
1
2018
1396
0.020
Why?
NF-kappa B
1
2016
424
0.020
Why?
Erythrocyte Count
1
2013
21
0.020
Why?
Calcitonin
1
2013
41
0.020
Why?
Carcinoembryonic Antigen
1
2013
40
0.020
Why?
Leg
1
2014
145
0.020
Why?
Vomiting
1
2014
109
0.020
Why?
Carrier Proteins
1
2016
670
0.020
Why?
Cotinine
1
2013
15
0.020
Why?
Receptor, ErbB-4
1
2013
5
0.020
Why?
Sensitivity and Specificity
1
2017
1946
0.020
Why?
Genetic Association Studies
1
2015
317
0.020
Why?
Erythropoietin
1
2013
90
0.020
Why?
HeLa Cells
1
2014
520
0.020
Why?
Microscopy, Atomic Force
1
2013
54
0.020
Why?
Pyrazoles
1
2014
162
0.020
Why?
Sequence Analysis, RNA
1
2014
273
0.020
Why?
Risk Reduction Behavior
1
2013
102
0.020
Why?
Tolonium Chloride
1
2012
9
0.020
Why?
Herpesvirus 4, Human
1
2013
127
0.020
Why?
Saliva
1
2013
134
0.020
Why?
Coloring Agents
1
2012
70
0.020
Why?
Microscopy, Confocal
1
2013
285
0.020
Why?
Asymptomatic Diseases
1
2012
48
0.020
Why?
Neoplasm Proteins
1
2015
553
0.020
Why?
Cells, Cultured
1
2016
2859
0.020
Why?
Supraglottitis
1
2011
3
0.020
Why?
Chemoradiotherapy, Adjuvant
1
2011
40
0.020
Why?
Self Report
1
2013
357
0.020
Why?
Physical Examination
1
2012
149
0.020
Why?
MAP Kinase Kinase Kinases
1
2011
44
0.020
Why?
Light
1
2012
289
0.020
Why?
Radiotherapy Planning, Computer-Assisted
1
2012
215
0.020
Why?
Cross-Over Studies
1
2011
394
0.020
Why?
Radiation Dosage
1
2011
233
0.020
Why?
Review Literature as Topic
1
2010
33
0.020
Why?
Osteoradionecrosis
1
2010
18
0.020
Why?
Postoperative Period
1
2010
325
0.020
Why?
Mercury Compounds
1
2009
1
0.020
Why?
Cadmium Compounds
1
2009
2
0.020
Why?
ROC Curve
1
2012
797
0.020
Why?
Laboratories
1
2009
47
0.020
Why?
Mice, Inbred C57BL
1
2016
3628
0.020
Why?
Nitrogen
1
2009
75
0.020
Why?
Tight Junctions
1
2010
158
0.020
Why?
Hospitalization
1
2014
993
0.020
Why?
Cyclin D
1
2008
15
0.020
Why?
Gene Dosage
1
2009
216
0.020
Why?
Transcription Factor AP-1
1
2008
68
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2010
889
0.020
Why?
Infant, Newborn
1
2014
2556
0.020
Why?
Azoxymethane
1
2008
84
0.020
Why?
Rats, Inbred F344
1
2008
161
0.020
Why?
Cyclins
1
2008
80
0.020
Why?
Equipment Design
1
2009
428
0.020
Why?
STAT3 Transcription Factor
1
2008
91
0.020
Why?
Technology, Radiologic
1
2008
105
0.020
Why?
Proto-Oncogene Proteins c-met
1
2009
199
0.020
Why?
Transfection
1
2009
884
0.020
Why?
Temperature
1
2009
446
0.020
Why?
Protein Structure, Tertiary
1
2009
733
0.020
Why?
Barrett Esophagus
1
2008
94
0.020
Why?
Glioblastoma
1
2010
301
0.020
Why?
Organ Preservation
1
2008
140
0.020
Why?
Child, Preschool
1
2014
4053
0.020
Why?
Polymorphism, Single Nucleotide
1
2015
2577
0.020
Why?
Blotting, Western
1
2008
779
0.010
Why?
p38 Mitogen-Activated Protein Kinases
1
2006
123
0.010
Why?
Phospholipids
1
2006
110
0.010
Why?
Body Mass Index
1
2009
869
0.010
Why?
Genome, Human
1
2010
834
0.010
Why?
Pleural Effusion
1
2004
43
0.010
Why?
Organoplatinum Compounds
1
2004
95
0.010
Why?
Administration, Topical
1
2003
80
0.010
Why?
RNA, Messenger
1
2010
2076
0.010
Why?
Membrane Proteins
1
2010
1293
0.010
Why?
In Situ Hybridization
1
2003
306
0.010
Why?
Survival
1
2002
22
0.010
Why?
Genome-Wide Association Study
1
2011
1863
0.010
Why?
Severity of Illness Index
1
2008
2025
0.010
Why?
Rats
1
2008
4079
0.010
Why?
Case-Control Studies
1
2006
2017
0.010
Why?
Registries
1
2006
1133
0.010
Why?
Cohen's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (683)
Explore
_
Co-Authors (56)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_